ERBB2 and breast carcinoma: In the older group, there was a significant difference in breast cancer subtype, with a decrease in patients with HR+/ERBB2– (PBC, 99 of 336 [29.46%]; CBC, 68 of 336 [20.24%]) and an increase in patients with ERBB2+ (PBC, 57 of 336 [16.96%]; CBC, 84 of 336 [25.00%]) (P = .002).